2021 Scientific Meeting
Claim CME - Coming on April 12, 2021
The ASCCP 2021 Scientific Meeting will present the most up-to-date research, guidelines, and technological advances in the prevention, screening, diagnosis, and management of anogenital and HPV-related diseases. A variety of pre-courses offer in-depth sessions on topics like vulvovaginal disease and anal cancer prevention. Presentations during the main meeting will address cutting edge data on a wide range of HPV topics including new technologies, head and neck disease, innovations in testing, immunization updates, and the impact of the microbiome. The meeting will highlight critical issues around implicit bias and deep disparities seen with HPV-related disease. Select oral abstracts will be presented. Members of the consensus committee that drafted the 2019 ASCCP risk-based management guidelines will explore lessons learned about implementation during the year since the guidelines were introduced.
Through an array of educational offerings, the ASCCP 2021 Scientific Meeting will bring together healthcare professionals from different backgrounds and experience levels who are interested in staying informed about the latest research dedicated to improving clinical outcomes and to reducing the burden of anogenital and HPV-related diseases around the world.
- Integrate into practice new insights from the latest research on prevention, diagnosis and management of anogenital and HPV-related diseases.
- Describe the biology, epidemiology, natural history, and immune response to HPV, as well as the societal costs associated with HPV infections.
- Successfully apply consensus guidelines for cervical cancer screening and management of cervical abnormalities to the general population as well as those in special circumstances.
- Successfully learn and apply novel screening and management strategies to underserved and under-screened individuals (transgender, incarcerated, etc.).
- Apply colposcopy to the diagnosis and management of anogenital and HPV-related diseases in ways that reflect its usefulness and maximum benefits while minimizing potential harms.
- Diagnose and treat HPV-related diseases including those that affect the cervix, vagina, vulva, anus, and head/neck. .
- Identify strategies for prevention and screening of HPV-associated oropharyngeal disorders.
- Review novel and experimental uses of therapeutic and prophylactic HPV vaccines, including the use of “catch-up” HPV immunization.
- Apply HPV testing and relevant diagnostic tests to clinical practice in a directed, evidence-based, cost-effective manner.
- Describe the vaginal microbiome and understand its impact on HPV clearance.
- Understand the impact of implicit bias on patient care and learn techniques to identify and address this bias.
- Apply data on HPV ecology to screening and management of patients who are postmenopausal.
- Manage positive cytology and HPV test results, high risk HPV genotype results, and histologically confirmed anogenital neoplasia, reflecting current and future patient risk of high grade neoplasia.
Note: The credit count below will be updated after all enduring material is posted on or around April 12, 2021.
Continuing Medical Education (CME)
ASCCP is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Category 1 Credit(s)TM
ASCCP designates this enduring activity for a maximum of 20 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NPWH (CE Credits)
This activity has been evaluated and approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women's Health for contact 20 contact hours, 0 contact hours of pharmacology. NPWH Activity number 21-06.
All those who have an opportunity to control content (Faculty, Program Directors, Reviewers, Staff, etc), are required to complete a COI based on the following instructions:
ASCCP members and the general public place great trust in the work of the Society. Real or perceived undisclosed conflicts of interest may jeopardize that trust and ASCCP’s effectiveness. Conflicts of interest also may affect the objectivity of decisions that ASCCP officers and volunteers make. To minimize the potential impact of possible conflicts of interest, the Board of Directors has determined that all participants in ASCCP activities must report all real or potential conflicts prior to the activity being developed and delivered to the learners. All disclosure forms are reviewed by the Course Director of each activity. Course Director disclosure forms are reviewed by ASCCP’s Education Committee. Most conflicts involve financial relationships with commercial interests. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. These may include pharmaceutical companies, device manufacturers or distributors, service companies, or other for-profit entities. Relationships with commercial interests may affect how officers or volunteers view products or services. They may also prompt outsiders to assume bias even when none exists, harming the reputation and effectiveness of the Society. Specific relationships with potential to create conflict of interest can include direct employment, management positions including directors and officers, royalties, consultants or board or advisory board positions, lecture fees paid by an entity (including membership on speakers bureaus or review panels), expert testimony especially to regulatory bodies or in litigation, ownership or beneficial ownership of stock or stock options, research funding, honoraria, gifts including travel or other in-kind payments (e.g., accommodations, sports tickets, appliances, electronic devices, etc.), intellectual property rights received or pending, and participation in sponsored research as a principal investigator. Contracted research funded by a commercial source also creates a potential conflict of interest; this includes research funding by which an employing institution receives a grant and manages funds and the CME provider serves as principal or named investigator on the grant. Investments made through diversified mutual funds or blind trusts in which the participant does not exercise decisional control are excluded. Usually primary employment by a nonprofit or governmental organization does not create potential for conflict, but compensation to employers based on an individual’s work with a for-profit company may create bias that must be reported. Income from commercial entities unrelated to health care does not create a potential for conflict of interest. By disclosing all relationships, participants and the Society allow others to judge the extent to which conflicts may have affected judgments in conscious or unconscious ways. If the potential for any relationship to create conflict of interest appears doubtful, then it should be disclosed.
This conference is supported by an unrestricted educational grant from Merck.